Published in Front Oncol on August 09, 2013
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A (2016) 0.85
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
A Simple Method for the Silver Impregnation of Reticulum. Am J Pathol (1936) 9.76
Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med (2003) 5.01
Pleural mesothelioma; further evidence of its histogenesis. J Thorac Surg (1950) 3.27
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax (2000) 2.83
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 2.18
Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med (2006) 1.84
TP53 family members and human cancers. Hum Mutat (2003) 1.70
WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res (2008) 1.67
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol (2005) 1.60
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res (2006) 1.44
Regeneration of parietal and visceral peritoneum: an electron microscopical study. J Anat (1973) 1.42
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene (2001) 1.18
Histogenesis and fine structure of peritoneal tumors produced in animals by injections of asbestos. J Natl Cancer Inst (1974) 1.18
Segmental duplications and evolutionary plasticity at tumor chromosome break-prone regions. Genome Res (2008) 1.16
Serosal tissue: reactive tissue as a model for understanding mesotheliomas. Ultrastruct Pathol (1987) 1.10
Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer (1989) 1.09
Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer (1994) 1.06
Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer (2001) 1.04
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer (2001) 1.02
Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res (1988) 1.02
Evidence for incorporation of free-floating mesothelial cells as a mechanism of serosal healing. J Cell Sci (2002) 1.00
Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci (2009) 1.00
Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation (2000) 0.99
Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res (1989) 0.94
Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer (1994) 0.91
Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp Cell Res (2000) 0.91
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer (2006) 0.90
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer (2009) 0.90
Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol (2005) 0.90
Cytokine regulation of mesothelial cell proliferation in vitro and in vivo. Eur J Cell Biol (1997) 0.88
Role of macrophages in mesothelial healing. J Pathol (1987) 0.87
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer (2008) 0.87
Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett (2006) 0.87
Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model. Anticancer Res (1996) 0.84
Beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion. Oncogene (2003) 0.82
Evolutionarily plastic regions at human 3p21.3 coincide with tumor breakpoints identified by the "elimination test". Genomics (2005) 0.81
Array-CGH and multipoint FISH to decode complex chromosomal rearrangements. BMC Genomics (2006) 0.81
Progressive growth of a human pleural mesothelioma xenografted to athymic rats and mice. Br J Cancer (1988) 0.80
Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch (2003) 0.79
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas. Clin Nucl Med (2016) 1.94
Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med (2006) 1.84
Determination of twelve heparin- and heparan sulfate-derived disaccharides as 2-aminoacridone derivatives by capillary zone electrophoresis using ultraviolet and laser-induced fluorescence detection. Electrophoresis (2002) 1.13
Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem (2006) 1.06
Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am J Pathol (2009) 1.02
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer (2002) 1.01
Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol (2003) 1.00
Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration. Int J Cancer (2010) 1.00
Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements. Exp Cell Res (2002) 0.99
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun (2013) 0.99
Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS One (2009) 0.97
Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. Int J Oncol (2012) 0.96
Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer (2011) 0.94
Mesothelial differentiation as reflected by differential gene expression. Am J Respir Cell Mol Biol (2003) 0.94
A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. Oncol Rep (2007) 0.93
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol (2008) 0.93
Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol (2006) 0.91
Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS One (2011) 0.90
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One (2013) 0.90
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer (2009) 0.90
Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol (2005) 0.90
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Mol Cell Proteomics (2013) 0.89
Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation (2007) 0.87
Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett (2006) 0.87
Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res (2003) 0.86
Compositional and structural alterations of chondroitin and dermatan sulfates during the progression of atherosclerosis and aneurysmal dilatation of the human abdominal aorta. Biochimie (2002) 0.86
Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2. PLoS One (2012) 0.85
Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells. PLoS One (2012) 0.85
Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells. Anticancer Res (2003) 0.83
Expression of p16(INK4a) in relation to histopathology and viral load of 'high-risk' HPV types in cervical neoplastic lesions. Eur J Cancer (2006) 0.82
Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. Acta Obstet Gynecol Scand (2010) 0.82
Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. In Vivo (2009) 0.82
Cartilage aggrecan undergoes significant compositional and structural alterations during laryngeal cancer. Biochim Biophys Acta (2006) 0.81
Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand (2003) 0.81
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma. PLoS One (2012) 0.80
The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol (2005) 0.80
Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res (2009) 0.80
The effect of body mass and physical activity on the development of guinea pig osteoarthrosis. Acta Orthop Scand (2003) 0.80
Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells. Anticancer Res (2004) 0.79
Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study. Clin Respir J (2008) 0.79
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One (2013) 0.79
Distribution of chondroitin 4-sulfate epitopes (2/B/6) in various zones and compartments of articular cartilage in guinea pig osteoarthrosis. Acta Orthop Scand (2003) 0.79
Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells. J Immunol (2011) 0.79
Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. Int J Oncol (2008) 0.79
Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer (2014) 0.78
High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities. Oncol Rep (2013) 0.78
p16(INK4a) immunocytochemistry in liquid-based cervical cytology: is it feasible for clinical use? Int J Oncol (2007) 0.78
Liquid-based cytology with HPV triage of low-grade cytological abnormalities versus conventional cytology in cervical cancer screening. Curr Pharm Des (2013) 0.77
Synthesis and expression of mRNA encoding for different versican splice variants is related to the aggregation of human epithelial mesothelioma cells. Anticancer Res (2003) 0.77
Presence of simian virus 40 (SV40) is not frequent in Swedish malignant mesotheliomas. Anticancer Res (2002) 0.77
A sandwich ELISA for the estimation of human syndecan-2 and syndecan-4 in biological samples. J Pharm Biomed Anal (2004) 0.76
Targeted therapy--possible new therapeutic option for malignant mesothelioma? Connect Tissue Res (2008) 0.76
[Well-founded role of HPV analysis in cervix cancer prevention]. Lakartidningen (2007) 0.75
[The bio terminology group recommends: Dare to nurture our professional language ]. Lakartidningen (2014) 0.75
[Open data important part of future research methodology]. Lakartidningen (2015) 0.75
[HPV test makes cytological examination more accurate. Cervical cancer can be discovered more efficiently]. Lakartidningen (2007) 0.75
Malignant mesothelioma--a connective tissue tumor with proteoglycan-dependent differentiation. Connect Tissue Res (2008) 0.75